Ex vivo activation characterization and targeting of the latent HIV infected reservoir to cure HIV

Recruiting

Conditions: Latent HIV infection
10047438

Registration Number: NL-OMON54790

Lead Sponsor: Erasmus MC, Universitair Medisch Centrum Rotterdam

Brief Summary: Not available

Detailed Description: Not available

Recruitment & Eligibility

Status: Recruiting

Sex: Not specified

Target Recruitment: 150

Inclusion Criteria

1. Age 18 years or older.
2. Confirmed HIV infectie

Exclusion Criteria

1. Inability to place 2.5 cm venous catheter or perform phlebotomy
2. Major comorbidities:
A. Severe symptomatic anemia
B. Recent symptomatic cardiovascular event.
3. The inability to participate due to any other relevant medical, social,
environmental, psychological, factors or according to the HIV treating
physician*s judgement.

Study & Design

Study Type: Observational invasive

Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
<p>The following endpoints refer to in vitro experiments:<br /><br>1. Descriptive analysis of latently infected HIV sub-populations of PBMC*s, by<br /><br>use of flow cytometry.<br /><br>2. Quantify increases transcription related factors before and after the<br /><br>addition of HIV expression modulating agents.<br /><br>3. To quantify the virologic response of latent HIV infected reservoir to<br /><br>treatment by HIV expression modulating agents.<br /><br>4. To explore potential biomarkers of the size of the HIV reservoir. These<br /><br>include cytokines (IFNg, IL1beta, IL2, IL4, IL6, IL8, IL10, IL-12p70, IL13,<br /><br>TNFalfa etc), HLA phenotyping (HLA B27 and B57), amount of HIV specific broadly<br /><br>neutralizing antibodies, SOMAscan (proteomics) level of HIV specific CTL<br /><br>activation and CD4+ T cel responses.<br /><br>5. Prospective clinical cohort<br /><br>6. Differences in HIV reservoir, shock and kill strategies, and immunity<br /><br>between different HIV clinical phenotypes</p><br>

Secondary Outcome Measures